ATHENS BIOSCIENCE, INC.™

20 October 2026

Change Control Notification Document #0018

Please distribute this information to the appropriate departments and personnel within your organization.

Description of Change
Athens Bioscience is notifying customers of a modification to the purification process used to manufacture native human Apolipoprotein C-II (Apo C-II).

The revised process incorporates improvements to the purification strategy to increase product recovery and manufacturing efficiency.

Affected Materials
This notification applies to native human Apolipoprotein C-II (Apo C-II) manufactured using the revised purification process.

Product Impact
The modification affects the manufacturing process used to isolate and purify Apo C-II. The product identity and intended use remain unchanged.

Material manufactured using the revised process has passed all applicable quality control tests. The source material, product release specifications, and associated documentation remain unchanged.

Timing of Change
The revised purification process was implemented in October 2026 and will be used for routine manufacturing of Apo C-II going forward.

Limited inventory produced using the previous purification process remains available. Customers requiring material manufactured using the previous process may request a custom production run, subject to availability and lead times.

Additional Information
Supporting product documentation may be requested for review.

For any questions regarding this notification, please contact our technical support team at technical@athensbioscience.com.

Best Regards,

Athens Bioscience